Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 57.2% from a year ago
Property, plant & equipment (net) stood at $269K at the end of Q1 FY2026, down 57.2% from a year earlier and down 24.2% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.
Context
- Property, plant & equipment (net) amounted to 0.3% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -57.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 355K USD
- Year-over-year change
- -51.7%
- 3-year CAGR
- +12.1%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 355K | -51.7% |
| FY2024 | 2024-12-31 | 735K | +374.2% |
| FY2023 | 2023-12-31 | 155K | -38.5% |
| FY2022 | 2022-12-31 | 252K | — |
Property, Plant & Equipment (Net) vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 property, plant & equipment (net) of $269K is the 10th highest of the 11 companies compared; the peer median is $21.1M.
- Its year-over-year change of -57.2% is the 10th highest of 11, against a peer median of -11.0%.
- Property, plant & equipment (net) amounts to 0.3% of total assets for AARD, versus a peer median of 15.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $69.55M | -9.3% | +34.8% | 22.1% | |
| Mar 2026 | $34.72M | -22.2% | -16.1% | 25.7% | |
| Mar 2026 | $32.1M | +1.8% | -12.7% | 14.4% | |
| Mar 2026 | $30.27M | -2.0% | -1.4% | 17.0% | |
| Mar 2026 | $23.48M | -38.3% | -11.2% | 15.8% | |
| Mar 2026 | $18.73M | -12.7% | -7.8% | 29.1% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $3.18M | +481.3% | +11.2% | 2.2% |
| Mar 2026 | $2.58M | -18.7% | -11.5% | 1.1% | |
| Mar 2026 | $375K | -60.5% | -42.4% | 0.4% | |
| Mar 2026 | $269K | -57.2% | +12.1% | 0.3% | |
ZURAZura Bio Limited | Mar 2026 | $125K | +17.9% | — | 0.1% |
| Peer median (excluding AARD) | $21.1M | -11.0% | -11.2% | 15.1% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.